Dr. Yue Liu has more than 20 years of experience in therapeutic antibody research and development and more than 10 years of experience in computer-aided therapeutic antibody design. She has led and participated in multiple therapeutic antibody studies on various diseases, including the development of anti-thrombotic antibodies for thrombi imaging and antibody-targeted thrombolysis, bispecific, tri-specific antibodies, and antibody drug conjugates to target cancer, anti-syn, and anti-tau antibodies for targeting PD and AD, as well as antibodies to target AMD and rare diseases. In 2017, Dr. Liu founded Ab Studio Inc. (www.antibodystudio.com) to perform AI/CAAD aided therapeutic antibody development.